About Us
Coordination
Secretariat Office:
IHU Méditerranée Infection, Aix-marseille University 19-21 bd Jean Moulin, 13005 Marseille, France
contact@medica2c.com
Coordinators of MediCA2C initiative
Jean-Marc Rolain
Sophie Baron
View biography
Steering Committee
Scientific Advisory Board
Education Lead
Surveillance Lead
Valorization Lead
Jean-Marc Rolain
Full Professor, PharmD, PhD, Aix-Marseille University, Public Assistance of Marseille Hospitals
Professor Jean-Marc Rolain is a full professor, clinical microbiologist at Aix-Marseille University and a leading investigator at IHU Méditerranée Infection, internationally recognized for his contributions to antimicrobial resistance (AMR) research.
With over 660 indexed publicationsand a H-index at 100, he has shaped global understanding of resistance mechanisms, reservoirs, and transmission pathways across the One Health spectrum.
He pioneered key bioinformatic tools such as ARG-ANNOT, now widely used for resistance-gene detection in surveillance genomics. His work has highlighted the ecological and evolutionary dynamics of multidrug-resistant Enterobacterales and the role of environmental agents such as pesticides in AMR emergence.
Pr. Rolain is a Highly Cited Researcher (2019–2021) and former Editor-in-Chief of the International Journal of Antimicrobial Agents. He has trained more than 200 students from over 25 countries—many now leaders in public health agencies, academia, and industry—thus reinforcing AMR surveillance capacity worldwide. He also contributed to several patents and biotech initiatives targeting diagnostics, decolonization, and resistance detection, supporting innovation in AMR monitoring and control.
Sophie Baron
Associate Professor, PharmD, PhD, Aix-Marseille University, Public Assistance of Marseille Hospitals
Dr. Sophie Baron is an Associate Professor of Medical Microbiology at Aix-Marseille University and AP-HM, working within IHU Méditerranée Infection. She holds a PharmD and a PhD in clinical microbiology.
Her research focuses on antimicrobial resistance within a One Health framework, with particular interest in how non-antibiotic chemical agents—especially pesticides—drive the emergence and dissemination of AMR. She also studies the success of high-risk clones of Klebsiella and Enterobacter and develops innovative diagnostic tools and therapeutic strategies.
Dr. Baron has expertise in genomics, bioinformatics, and clinical microbiology. She contributes to surveillance initiatives by characterizing AMR epidemiology in humans, animals, and the environment, and by elucidating resistance mechanisms in multidrug-resistant bacteria.
